Drug Discovery and Development Solutions for Retinal Degeneration

Our In Vitro Efficacy Testing Service accelerates retinal degeneration drug discovery by providing sensitive, reproducible screening and characterization platforms. Utilizing advanced biochemical and cell-based assays—including FRET, fluorescent, luciferase, and radioactivity methods—we evaluate compound effects on key targets such as GSK3β, Htra1, Rpe65, and Rhodopsin. We deliver essential pharmacological parameters (EC-50, IC-50, Kd, MIC) to assess potency, efficacy, and binding affinity. This comprehensive approach enables efficient ranking and optimization of drug candidates, supporting informed decision-making and risk reduction in preclinical research for therapies targeting retinal degeneration mechanisms.

Ace Therapeutics provides comprehensive in vivo animal model development services for retinal degeneration, supporting drug discovery and preclinical validation. Utilizing 33 validated mouse and rat models—including chemically-induced, light-induced, and genetic paradigms—we accurately replicate human retinal diseases. Our end-to-end solutions encompass model selection, induction, therapeutic administration, and advanced phenotypic analysis (histology, OCT, ERG, molecular profiling). Rigorous quality control, experienced staff, and state-of-the-art analytical platforms ensure data reliability and reproducibility. We offer tailored, scientifically robust models and expert support, accelerating translational research and enabling efficient development of novel therapies for retinal degenerative disorders.

Our PK/PD research service for retinal degeneration offers comprehensive evaluation of drug candidates using advanced modeling, diverse administration routes, and detailed compartment analysis in relevant animal models. We utilize cutting-edge analytical techniques such as HPLC and LC-MS for precise quantification of compounds and biomarkers. Our expertise enables in-depth understanding of absorption, distribution, metabolism, and excretion, supporting optimal dosing strategies and translational success. By integrating robust experimental platforms and scientific insight, we empower partners to accelerate drug development and maximize efficacy, ultimately advancing innovative therapies for patients with vision-threatening retinal diseases.

Ace Therapeutics offers comprehensive in vivo toxicity assessment services tailored for retinal degeneration therapeutics. Utilizing advanced methodologies, including acute and chronic toxicity studies, organ-specific ocular evaluations, and state-of-the-art imaging and molecular assays, we ensure thorough safety profiling. Our expertise spans multiple validated animal models, with specialized techniques such as OCT, ERG, and retinal flat-mount analysis. Adhering to GLP standards and international guidelines, we deliver robust, reproducible data to support regulatory submissions. Our integrated approach empowers partners to mitigate risk, accelerate development, and confidently advance novel vision loss therapies from preclinical research to clinical trials.

Ace Therapeutics offers research-focused biomarker analysis services for retinal degeneration, utilizing multi-omics strategies to explore molecular and cellular mechanisms. We employ genomics, transcriptomics, proteomics, and metabolomics platforms to screen and evaluate candidates with potential as biomarkers. Our methodologies encompass high-throughput screening, multiplexed assays, and advanced imaging, supporting the assessment of molecular signatures relevant to retinal disease. Through rigorous experimental and computational approaches, we investigate the utility of targets such as PDE6B, RPE65, RHO, and USH2A. Our technical expertise enables comprehensive evaluation of biomarker candidates, advancing preclinical drug discovery and understanding of retinal degeneration pathophysiology.